Tumor cells with increased immunogenicity and uses therefor

Details Tumor cells with increased immunogenicity and uses therefor Tumor cells with increased immunogenicity and uses therefor

1998-09-23

2000-11-21

Hauda, Karen M.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

424 932, 424 92, 435375, 4353201, 435 691, 514 44, A61K 4800

Patent

active

061499056

ABSTRACT:
Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

REFERENCES:
Baskar; S. et al. (1993) "Constitutive Expression of B7 Restores Immunogenicity of Tumor Cells Expressing Truncated major Histocompatibility Complex Class II Molecules" Proc. Natl. Acad. Sci. USA 90:5687-5690.
Bateman, W.J. et al. (1991) "The Effect of Class II Gene Transfection on the Tumourigenicity of the H-2K-Negative Mouse Leukaemia Cell Line K36. 16" Immunology 172:213-218.
Chen, L. et al. (1992) "Constimulation of Antitumor Immunity by the B7 Counterreceptor For the T Lymphocyte Molescules CD28 and CTLA-4" Cell 71:1093-1102.
Clements, Virginia K. et al. (1992) "Invariant Chain Alters The Malignant Phenotype of MHC Class II.sup.+ Tumor Cells" Journal of Immunology 149:2391-2396.
Cole, G.A. et al. (1991) "Rejection of Allogeneic Tumor Is Not Determined by Host Responses to MHC Class I Molecules and is Mediated By CD4.sup.- CD8.sup.+ T Lymphocytes That Are Not Lytic for the Tumor" Cellular Immunology 134:480-490.
Fearon, E.R. et al. (1990) "Interleukin-2 Production By Tumor Cells Bypasesses T Helper Function in the Generation of An Antitumor Response" Cell 60:397-403.
Freeman, G.J. et al. (1991) "Structure, Expression, and T Cell Costimulatory Activity of The Murine Homologue of the Human By Lymphocyte Activation Antigen B7" J. Exp. Med. 174:625-631.
Freeman, G.J. (1989) "B7, A New Member of the Ig Superfamily With Unique Expression on Activated and Neoplastic B Cells" J. Immunology 143:2714-2722.
Freedman, A.S. et al. (1987) "B7, A B Cell-Restricted Antigen That Identifieds Preactivated B. Cells" J. Immunology 139:3260-3267.
Galvin, F. et al. (1992) "Murine B7 Antigen Provides A Sufficient Costimulatory Signal For Antigen-Specific and MHC-Restricted T Cell Activation" J. Immunology 149:3802-3808.
Ostrand-Rosenberg, S. et al. (1990) "Rejection Of Mouse Sarcoma Cells After Transfection of MHC Class II Genes" J. Immunology 144:4068-4071.
Reiser, H. et al. (1992) "Murine B7 Antigen Provides an Efficient Costimulatory Signal For Activation of Murine T Lymphocytes Via the T-Cell Receptor/CD3 Complex" Proc. Natl. Acad. Sci. USA 89:271-275.
Schultz, K.R. et al. (1990) "The Role of B Cells For In Vivo T Cell Resp;onses To A Friend Virus-Induced Leukemia" Science 249:921-923.
Tan, P. et al. (1993) "Induction of Alloantigen-Specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1" J. Exp. Med. 177:165-173.
Thompson, C.B. et al. (1989) "CD28 Activation Pathway Regulates the Production of Multiple T-Cell-Derived Lymphokines/Cytokines" Proc. Natl. Acad. Sci USA 86:1333-1337.
Towsend, S.E. et al. (1993) "Tumor Rejection After Direct Costimulation of CD8.sup.+ T Cells by B7-Transfected Melanoma Cells" Science 259:368-370.
Townsend, S.E. et al. (1993) "Expression of the T Cell Costimulatory Ligand B7 By A Melanoma Induces Rejection Mediated By Direct Activation of CD8+ T Cells" J. Cell Biochem. Supplement (Abstract NZ 627) p. 136.
Travis, J. (1993) "A Stimulating New Approach to Cancer Treament" Science 259:310-311.
Uhlmann, Eugen (1990) "Antisense Oligonucleotides: A New Therapeutic Principle" Chemical Reviews 90:544-584.
van Der Bruggen, P. et al. (1991) "A Gene Encoding An Antigen Recognized By Cytolytic T Lymphocytes On A Human Melanoma" Science 254:1643-1647.
Gimmi, C.D. et al. (1991) "B-Cell Surface Antigen B7 Provides A Costimulatory Signal That Induces T Cells to Proliferate and Secrete Interleukin 2" Proc. Natl. Acad. Sci. USA 88:6575-6579.
Gimmi, C.D. et al. (1993) "Human T-Cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation" Proc. Natl. Acad. Sci. USA 90:6586-6590.
Harding, F.A. et al. (1992) "CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones" Nature 356:607-609.
Harding, F.A. et al. (1993) "CD28-B7 Interactions Allow the INduction of CD8.sup.+ Cytotoxic T Lymphocytes in the Absence of Exogenous Help" J. Exp. Med. 177:1791-1796.
James, R.F.L. (1991) "The Effect of Class II Gene Transfection on the Tumourigenicity of the H-2K-neative Mouse Leukaemia Cell Line K36. 16" Immunology 172:213-218.
Koch, Norbert et al. (1987) "Primary Structure of the Gene for the Murine Ia Antigen-associated Invariant Chains (Ii). An Alternatively Spliced Exon Encodes a Cysteine-Rich Domain Highly Homologous to a Repetitive Sequence of Thyroglobulin" The EMBO Journal 6:1677-1683.
Linsley, P.S. et al. (1991) "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and INterleukin 2 mRNA Accumulation" J. Exp. Med. 173:721-730.
Nabavi, N. et al. (1992) "Signalling Through the MHC Class II Cytoplasmic Domain Is Required For Antigen Presentation and Induces B7 Expression" Nature 360:266-268.
Ostrand-Rosenberg, S. et al (1993) "Costimulation Through Murine B7 Molecule Restores Immunogenicity of Autologous Tumor Cells Expressing Truncated MHC Class II Molecules" J. Cell Biochem Supplement (Abstract HZ 228) p. 71.
Ostrand-Rosenberg, S. et al. (1991) "Abrogation of Tumorigenicity By MHC Class II Antigen Expression Requires The Cytoplasmic Domain of the Class II Molecule" J. Immunology 147:2419-2422.

Affiliated with

Also associated with

Rating

Tumor cells with increased immunogenicity and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor cells with increased immunogenicity and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor cells with increased immunogenicity and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1254264